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RESEARCH ARTICLE
Health Disparities between Black Hispanic and Black NonHispanic Cervical Cancer Cases in the USA
Hafiz Mohammad Rafiqullah Khan1*, Kemesha Gabbidon2, Faheema AbdoolGhany1, Anshul Saxena2, Esneider Gomez1, Tiffanie Shauna-Jeanne Stewart3
Abstract
Background: Globally, cervical cancer is a major public health concern. Cervical cancer is the second most
common cancer among women, resulting in approximately 500,000 cases per year. The purpose of this study is
to compare disease characteristics between Black Hispanic (BH) and Black non-Hispanic (BNH) women in the
US. Materials and Methods: We used stratified random sampling to select cervical cancer patient records from
the SEER database (1973-2009). We used Chi-square and independent samples t-test to examine differences in
proportions and means. Results: The sample included 2,000 cervical cancer cases of Black non-Hispanic and 91
Black Hispanic women. There were statistically significant differences between black Hispanic and black nonHispanics in mean age at diagnosis (p<0.001), mean survival time (p<0.001), marital status (p<0.001), primary
site of cancer (p<0.001); lymph node involvement (p<0.001); grading and differentiation (p<0.0001); and tumor
behavior (p<0.001). Black women were more likely to develop cervical cancer and to have the highest mortality
rates from the disease. Conclusions: Findings from this study show clear racial and ethnic disparities in cervical
cancer incidence and prognosis that should be addressed.
Keywords: Cervical cancer data - ethnicity - Black Hispanic - Black non-Hispanic - statistical analysis
Asian Pac J Cancer Prev, 15 (22), 9719-9723

Introduction
Globally, cervical cancer is responsible for an
estimated 500,000 cases and 227,000 deaths annually
(WHO, 2013a). Developing nations face issues of poorly
developed and financially unsupported cervical cancer
screenings programs (Farmer et al., 2010). Therefore, most
cases of cervical cancer occur in low and middle income
countries and the majority of cases are diagnosed in the
later stages of the disease (Farmer et al., 2010; Scarinci et
al., 2010). Developed nations also face high cervical cancer
incidence and prevalence. In the years between 2006 and
2010, US women faced a cervical cancer incidence of 7.9
per 100,000 (SEER, 2013). Most forms of cervical cancer
are caused by the human papillomavirus (HPV), which
has over a 100 subtypes (Saslow et al., 2012). Most of the
subtypes are benign and without treatment will typically
disappear within two years. Thirteen of the 100 subtypes
have been described as malignant, the most virulent of
which are HPV 16 and 18 (WHO, 2013a). HPV 16 and
18 are responsible for 70% of all cervical cancers and
precancerous cervical changes (WHO, 2013a). Symptoms
of cervical cancer include vaginal bleeding and discomfort
after sexual intercourse, pelvic and back pain, and weight

and appetite loss (WHO, 2013a).
Transmitted by skin-to-skin contact and sexual
intercourse, HPV is the most common viral infection
affecting the reproductive tract (WHO, 2013a). It causes
cervical dysplasia, which may develop into premalignant
lesions. The type of HPV also affects the grade of cervical
cancer (Hariri et al., 2014). MRI scans are used to detect
the grade of cervical cancer, which helps practitioners to
determine the best course of treatment (Sala et al., 2010).
Cervical intraepithelial neoplasia 1, 2, and 3 (CIN1,
CIN2, and CIN3) are grades of premalignant lesions
which can develop into cervical cancer without treatment
(WHO, 2013b). CIN3 is the focus of most cervical cancer
screenings in the United States, however, some physicians
may provide treatment at the CIN2 stage (Schiffman et
al., 2011).
Cervical cancer screenings are important because they
result in early detection and early treatment of disease,
however, there are differences among screening patterns
of different ethnicities (Smith et al., 2011; Simard et al.,
2012; Haile et al., 2012). Because of these disparities, it
is imperative to assess the differences in cervical cancer
survival across ethnicities. Furthermore, ethnicities
differ in stage of cancer, which is an important factor in
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predicting patients’ prognosis (Maltoni et al., 2012).
Preventing cervical cancer requires reducing the
development of pre-cancers by increasing screening and
reducing exposure to HPV. These precancerous changes
and invasive cervical cancer are readily detected by
routine Papanicolaou tests (Pap test) (Pierce-Campbell
et al., 2012). It is recommended that cervical cancer
screening begin at age 21 despite level of sexual activity
or age at sexual initiation (Saslow et al., 2012). Current
cervical cancer screening recommendations, state that
women who are between the ages of 21 and 29 complete
a screening with cytology every 3 years. In addition, for
women between ages 30 to 65 it is recommended that they
receive cytology alone every 3 years or screening with
cytology and HPV testing every 5 years (Moyer, 2012;
Saslow et al., 2012). Because of the 15 to 20 year time
span between exposure and cervical cancer development,
current screening recommendations do not require annual
exams (Saslow et al., 2012; WHO, 2013a). Instead,
women are urged to screen every three years (CDC, 2013).
Currently, there are two prophylactic vaccines Cervarix
and Guardasil, which have been approved by the US Food
and Drug Administration (FDA). These two vaccines
protect against HPV 16 and 18 and are recommended
for females between the ages 11 and 16 (DeSantis et al.,
2013; Pierce-Campbell et al., 2012; Saslow et al., 2012;
Schiffman et al., 2011; WHO, 2013a). Overall, vaccination
rates have increased since 2006; however, the rates remain
dismally low. For example, less than 50% of US adolescent
girls receive one dose of the vaccine and approximately
one third have received all 3 doses (Pierce-Campbell et
al., 2012; Saslow et al., 2012).
To determine the severity of cancer and the best
therapy, physicians use biopsies, colposcopy, computerized
tomography (CT) scans, and magnetic resonance imaging
(MRI). Developments in the ability of screening tests to
detect will results in an increase in detection of CIN2 and
CIN3(Schiffman et al., 2011). Treatment of cervical cancer
may include removal of all CIN3 cervical cells including
a surrounding layer of healthy cells (Schiffman et al.,
2011). Localized cancer treatment includes the removal
of all cancerous tissue by conization and sometimes a
hysterectomy. If the cancer is no longer localized, a radical
hysterectomy is used which includes removal of the
uterus, cervix, and parts of the vagina (NCI, 2013). This
is sometimes followed by a combination of chemotherapy
and radiation.
Previous studies have identified that screening
and cancer characteristics vary among ethnicities. For
example, white non-Hispanic women have a lower
incidence of cervical cancer compared to Hispanic women.
In addition, there are varying cervical cancer screening
rates and incidence across the Hispanic race (Seigel et al.,
2012). According to the American Cancer Society, a higher
proportion of Puerto Rican women (83.0%) in 2011 was
screened for cervical cancer, in comparison to white nonHispanic women (79.1%), and Mexican women (71.6%)
(ACS, 2012). Hispanics can be categorized as black
Hispanic or white Hispanic (Khan et al., 2014a). Khan
et al. (2014a) developed statistical probability model and
posterior inference for the parameters given the survival
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times of the white Hispanic female cancer patients.
Determinants of cervical cancer include race,
ethnicity, socioeconomic status, and geographic location.
There has been a consistent failure in reaching the most
disadvantaged and at risk populations (Glick et al., 2012;
Saslow et al., 2012; Simard et al., 2012). An increase in
cervical cancer screening between the years 1993 and
2007 has resulted in a decline in cervical cancer related
mortality. This decrease however, did not occur among
those with low education levels. Among Hispanics,
cervical cancer disparities increased among black nonHispanics (5x) and white non-Hispanic (4x) (Niccolai et
al., 2013). Furthermore, there are cervical cancer incidence
differences between racial groups. For example, in 2012,
Hispanics had 10.9 cases per 100,000 , blacks 9.6 cases per
100,000 , whites 7.9 cases per 100,000, American Indians
and Alaska Natives 7.3 cases per 100,000, and Asians and
Alaska Natives 6.6 cases per 100,000 (Pierce-Campbell et
al., 2012; SEER, 2013). Between the years 2006 and 2010,
blacks experienced the highest mortality rates at 4.2 deaths
per 100,000, followed by Alaska Natives and American
Indians with 3.5 deaths per 100,000, Hispanics with 2.9
deaths per 100,000, whites with 2.2 deaths per 100,000,
and Asians with 1.9 deaths per 100,000. Interestingly,
blacks experienced similar cervical cancer rates as
Vietnamese and Koreans (Siegel et al., 2012; Wang et
al., 2010). In addition, blacks reported the highest rates of
late stage cervical cancer diagnosis (Simard et al., 2012).
The high rates of cervical cancer nationally and
internationally along with low vaccine uptake makes it
important to continue to reduce cervical cancer rates.
Cervical cancer is a highly preventable disease and
research is needed to provide the best tools to determine
patient prognosis and the effective therapies. This study
examines racial disparities in cervical cancer rates by using
national cancer registry data. We examine the differences
in demographic and disease characteristics between BNH
and BH.

Materials and Methods
The study used data from the Surveillance
Epidemiology and End Results (SEER) database (19732009). SEER is a comprehensive database, which began
in 1973 collecting data for seven states. Currently, SEER
collects and publishes cancer incidence and survival
information from cancer registries covering 28% of the US
population throughout the United States (SEER, 2013.).
We matched ICD-O-3 site diagnosis codes (C530=
Endocervix; C531= Exocervix; C538= Overlap lesion
cervix uteri; and C539= Cervix uteri), and SEER database
site recode (#27010) for cervical and uterine cancers
(resulting in 165,069 cervical cancer cases between years
1973 and 2009) as a part of the data extraction process.
We then sorted them by race and ethnicity resulting in
127,428 cases among whites and 20,471 cases among
blacks. Of the black group, 20,324 [99.6%] were BNH,
and remaining 91 [0.4%] were BH. From here, a simple
random sampling was used to select 2,000 cases of black
non-Hispanic females and 91 cases of black Hispanic
females for a total study sample of 2091 women diagnosed
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with cervical cancer. For more information of selection of
patients by making use of random sampling, readers are
referred to Khan et al. 2014b, 2014c, 2014d, and 2014e.
In addition, we used subject’s demographic information
(age at diagnosis and marital status) as well as cervical
cancer information (tumor primary site, grading, behavior,
and lymph node involvement) from the SEER dataset for
statistical analysis.
Data analysis was performed using IBM SPSS
software (IBM SPSS for Windows version 20, 2011).
Comparisons of BNH and BH were conducted using
either an independent sample t-test or a Pearson’s chisquared test of independence (Table 1 & 2). Alpha level
(α = 0.05) was used to determine statistical significance.
Furthermore, we examined the histological characteristics
(Table 3), and 5-year relative survival rates (Table 4) for
cervical cancer.

Results
When comparing demographic characteristics across
the two groups (Table 1), there were significant differences
between the mean age at diagnosis (in years), mean
survival days (in months), and marital status (p<0.001).
The mean age of diagnosis for black non-Hispanic
women represented a 0.25 decrease from black Hispanic
women. Though mean age of diagnosis did not differ
greatly between these two groups, it was still statistically
significant at alpha 0.05.
Survival days (in months) were also observed. Overall
there is a significant difference in mean survival days
(p <0.001 at alpha 0.05) between groups. There is a
4.54-month difference between the two groups, where
black non-Hispanics are more likely to live longer than
black Hispanics, suggesting that ethnicity could play a
role in the latency of cervical cancer.
The last demographic characteristic that was observed
was marital status. Being single was the most common
relationship status reported for both black non-Hispanics
and black Hispanics. Both groups followed a similar
trend for five of the six options that were presented. The
status for “unknown” was the third most frequent option
that was selected among black Hispanics accounting for

Table 1. Demographic Characteristics for black nonHispanic and black Hispanic
Characteristics

black non-Hispanic black Hispanic
(n=2000)
(n=91)

Age at Diagnosis			
Mean
40.04*
40.29
Median
35
37
Std. Deviation
16.5
15.523
Survival Days (years)			
Mean
16.54*
12.00*
Median
16.83
13.25
Std. Deviation
10.75
7.84
Marital Status			
Single
669 (33.5%)
31 (34.1%)
Married
580 (29.0%)
24 (26.4%)
Separated
123 (6.2%)
4 (4.4%)
Divorced
223 (11.2%)
9 (9.9%)
Widowed
212 (10.6%)
3 (3.3%)
Unknown
193 (9.7%)
20 (21.9%)

p-value

21.9% (20) of those who were interviewed.
Table 2 deals with the primary site of cervical cancer
between the two groups, black non-Hispanic, and black
Hispanic, which was the cervix/uteri (92.6% & 83.5%,
respectively). The end cervix was the second most
prevalent site among black non-Hispanics and black
Hispanics (4.5% and 8.8%, respectively). The exocervix
accounted for 4.4% (4) of black Hispanics, which differed
from the 0.08% (15) of black non-Hispanics. The overlap
lesion cervix uteri, was the least prevalent among all the
groups.
Of the cases that reported lymph node involvement,
almost all had no involvement, accounting for no more
than 14% for each group. From those reported, about half
was unknown, or was not stated, 4.7% (94) black nonHispanics and 8.8% (8) black Hispanics.
In comparing grading and differentiation, for those
cases that were graded, most were either grade II or III.
About 13.2% (12) black Hispanics reported Grade II, and
8.8% (8) reported Grade III. Whereas, 7.0% (140) of black
non-Hispanics reported grade II, and 9.4% (188) reported
grade III. Less than 1% of individuals that participated
reported grade IV. Cell type was not determined, not stated
or not applicable for 81.2% (1625) of black non-Hispanic
Table 2. Cervical Cancer Characteristics for black
non-Hispanic and black Hispanic
Characteristics

black non-Hispanic black Hispanic p-value
(n=2000)
(n=91)

Primary Site			
Endocervix (C530)
89 (4.5%)
8 (8.8%) <0.001‡
Exocervix (C531)
15 (0.8%)
4 (4.4%)
Overlap lesion cervix uteri (C538)
		
45 (2.3%)
3 (3.3%)
Cervix uteri (C539)
1851 (92.6%) 76 (83.5%)
Lymph node Involvement (1988-2003) 			
No lymph node involvement 638 (31.9%) 54 (59.3%) <0.001‡
Regional lymph node(s)
26 (1.3%) 5 (5.5%)
Aortic (para-, peri-, lateral)
6 (0.3%) 0 (0.0%)
Other
6 (0.3%) 1 (1.1%)
Unknown; not stated
94 (4.7%) 8 (8.8%)
Grading and Differentiation			
Grade I
29 (1.5%) 2 (2.2%) <0.001‡
Grade II
140 (7.0%) 12 (13.2%)
Grade III
188 (9.4%) 8 (8.8%)
Grade IV
18 (0.9%) 1 (1.1%)
Cell type not determined, not stated or not applicable
1625 (81.2%)
68 (74.7%)
Behavior			
In situ
1346 (67.3%) 53 (58.2%) <0.001‡
Malignant
654 (32.7%) 38 (41.8%)
‡Chi-square test

<0.001†

Table 3. Histological Characteristics for Cervical
Cancer black Non-Hispanic and black Hispanic
Broad groupings

<0.001†

<0.001‡

*Level of significant, α = 0.05; †Independent sample t-test; ‡Chi-square test

black black
non-Hispanic Hispanic

Unspecified neoplasms
5
Epithelial neoplasms, NOS
696
Squamous cell neoplasms
1202
Basal cell neoplasms
1
Adenomas and adenocarcinomas
66
Cystic, mucinous and serous neoplasms
4
Ductal and lobular neoplasms
1
Complex epithelial neoplasms
20
Soft tissue tumors and sarcomas, NOS
1
Myomatous neoplasms
0
Complex mixed and stromal neoplasms
4
‡Chi-square test

0
19
70
0
2
0
0
0
0
0
0

Total

P-value

17 (0.3%) <0.001‡
1811 (29.7%)
3923 (64.4%)
1 (0.1%)
256 (4.2%)
14 (0.2%)
1 (0.1%)
52 (0.9%)
1 (0.1%)
5 (0.1%)
10 (0.2%)
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Table 4. Five Year Relative Survival for Cervical Cancer
Year
2010

All Races
All Ages
68.10%

Ages<50
77.90%

White
Ages 50+
56.10%

All Ages
69.50%

and 74.7% (68) black Hispanic.
Histological and behavior characteristics of cervical
cancer suggests that majority of the cases had carcinoma
in-situ (67.3% and 58.2%, respectively) and were
malignant (32.7% and 41.8% respectively).
Table 3 presents the breakdown of histological
characteristics of cervical cancer by broad groupings. In
most cases, across the two ethnic groups, cervical cancer
was of a squamous cell origin (64.4%). It appears that the
black non-Hispanic sample was the only one to be affected
by basal cell neoplasms, ductal & lobular neoplasms, and
soft tissue tumors & sarcomas, NOS. Basal cell neoplasms,
cystic mucinous and serous neoplasms, ductal and lobular
neoplasms, complex epithelial neoplasms, soft tissue
tumors and sarcomas (NOS), myomatous neoplasms, and
complex mixed stromal neoplasms accounted for no more
than 1%, where each group had no more than 5 patients
in each. More than 50% of black non-Hispanic patients
were diagnosed with squamous cell neoplasms.
Table 4 shows the overall 5-year survival rate for
cervical cancer (2010) as well as race and age categories.
The 5-year survival is significantly different when broken
down by race: black (58.2%) vs. white women (69.5%)
(Howlader et al., 2014). White patients who are diagnosed
are 8.5% more likely to survive than Black patients.

Discussion
Findings have demonstrated that there are clear racial
and ethnic differences in cancer diagnosis and survival. Of
the two ethnic groups studied, black Hispanic women are
by far the most affected by the disease. When investigating
age of diagnosis and survival time, black women were
diagnosed at a more advanced age and would succumb
to the disease sooner when compared to their white
counterparts. These findings are consistent with previous
studies suggesting that even though the overall incidence
and mortality rates of cervical cancer have declined, the
rates among minorities continue to be disproportionally
high (Downs et al., 2008; CDC, 2011).
As the mean age at diagnosis ranged from age 38 to 40,
it is important for women at or over the age 21, to begin and
continue screenings as recommended. Because cervical
cancer takes, approximately 15 to 20 years to develop
women should begin screening at the recommended age
to identify and treat pre-cancers and prevent progression
to cervical cancer. These study findings give credence to
the importance of early detection and treatment in reducing
cervical cancer. Although all women will benefit from
early and consistent cervical cancer screenings, increased
efforts need to be made to lengthen the survival time for
black Hispanics. In addition, there may be several social
and behavioral determinants that affect the survival time
of this group.
The study also finds that across the two ethnic
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Ages<50
79.70%

Blacks
Ages 50+
56.20%

All Ages
58.20%

Ages<50
64.20%

Ages 50+
52.40%

groups investigated that the histologic origin of the
cervical cancer was overwhelmingly attributed to the
squamous cell neoplasms subtype (64.4%). This was
followed by epithelial neoplasms (29.7%) and adenomas/
adenocarcinoma subtypes (4.2%). These findings are
consistent with a similar study that investigated the
histologic subtypes of cervical cancer in reference to race
and disease stage (Wang et al., 2004).
Furthermore, it appears that black non-Hispanics
may have an increased chance of developing rare forms
of cervical cancer such as basal cell neoplasms, ductal,
lobular neoplasms, NOS, soft tissue tumors, and sarcomas.
This implies that racial and ethnic differences may also
affect type of cancer developed within certain ethnicities.
Despite the obvious strengths of this study, such
as the use of a nationally recognized cancer database,
SEER, which has collected and published critical cancer
statistics for over thirty years from cancer registries
throughout the United States, with reliable information
on incidence, mortality and other included variables some
limitations should be noted. A shortcoming of the study
was the lack of black Hispanic females registered in the
SEER database, therefore limiting our inclusion of this
ethnic/racial subgroup to just 91 women. To summarize,
the findings of this study stressed the fact that the health
disparity in cervical cancer is still very much prevalent.
Although there has been a concerted effort to implement
policies aiming to close the gap on health outcomes in
regards to cervical cancer, they have thus far failed to
accomplish this goal specifically when comparing Blacks
to the White majority. Health care and public health efforts
need to target the most disadvantaged communities and
improve health equity in regards to cervical cancer. This
may include improving the treatment options for these
groups and improving screening efforts to ensure earlier
disease detection.
Study results suggest that there is a difference
between the two ethnic groups; black Hispanic and
black non-Hispanic. Demographic, cervical cancer and
histologic characteristics are all statically significant
from one another. These findings were limited by the
unequal sample size, which black Hispanics consisted
of 91 patients. Additional barriers were the limitation of
previous medical history and preventative measures that
were taken by each ethnic group.
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